Breast Carcinoma In Situ clinical trials

The registry lists 190 studies for Breast Carcinoma In Situ across more than 10 countries. 25 are recruiting or about to start. 57 of them are mainly about Breast Carcinoma In Situ (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-13. Counting its narrower condition Carcinoma, Intraductal, Noninfiltrating too: 385 studies, 71 open.

Get an email when these change. Save the Breast Carcinoma In Situ studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed: 109
Recruiting: 23
Active, not recruiting: 17
Terminated: 17
Status unknown: 11
Withdrawn: 8

Phase

Phase 2: 50
Phase 1: 18
Phase 3: 18
Early Phase 1: 2
Phase 4: 2

Where

United States: 151
Canada: 10
Puerto Rico: 6
United Kingdom: 6
Italy: 6
Switzerland: 5

Who runs them

Mayo Clinic (14) · Ohio State University Comprehensive Cancer Center (11) · National Cancer Institute (NCI) (11) · Alliance for Clinical Trials in Oncology (7) · Jonsson Comprehensive Cancer Center (6) · SWOG Cancer Research Network (5) · City of Hope Medical Center (5) · Wake Forest University Health Sciences (4)

What is being tested here

Drugs under test in Breast Carcinoma In Situ studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug	Open	Phase 3	All
Tamoxifen	2	3	16
Trastuzumab	1	0	2
Taxane	1	0	1
TLR7 Agonist CAN1012	1	0	1
Acolbifene	1	0	1
Starch, potato	1	0	1
Anastrozole	0	2	5
Letrozole	0	1	5
Metformin	0	1	2
Paclitaxel	0	1	2

Drug classes tested here SERMs 2 open · Aromatase inhibitors 10 · Statins 5 · NSAIDs 4 · Antimitotic agents 3

Coming up

2phase 3 studies under way

16studies finish main data collection within a year

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest

Dec 2026The PREDICT Registry: · PreludeDx
Dec 2026Hypofractionated Radiation Therapy vs Standard Treatment in Breast Cancer. · Coordinación de Investigación en Salud, Mexico
Dec 2026Web-Based Symptom Monitoring and Self-Management Portal (YES) for Adolescent and Young Adult Breast Cancer Survivors · Ohio State University Comprehensive Cancer Center
Dec 2026The Added Value of Contrast Enhanced Mammography to Standard Mammography in Assessing the Extent of DCIS · Clinical Hospital Center Rijeka
Dec 2026Manual Lymphatic Drainage Breast Massage in Breast Cancer Patients After Breast Conserving Surgery · University of Southern California
Jan 2027EXERT-BCH Exercise Regimen to Improve Muscle Mass After Treatment of Breast Cancer · Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Jan 2027Trastuzumab Plus Taxane Neoadjuvant Therapy for HER2-Positive Breast Ductal Carcinoma In Situ (DCIS) : A Phase II Study · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Jan 2027Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction · National Cancer Institute (NCI)
Feb 2027Standard Verbal Counseling With or Without a Pictorial Educational Tool for the Reduction of Psychological Morbidity in Patients With Stage 0-IIIA Breast Cancer Receiving Radiation Therapy, COPE Study · OHSU Knight Cancer Institute
Apr 2027Hypnosedation in Relaxing Patients Undergoing Breast Cancer Surgery · M.D. Anderson Cancer Center

Who these studies take

Of the 23 Breast Carcinoma In Situ studies recruiting now, 17 (74%) set no upper age limit and 4 (17%) stop at 75 or younger. 1 (4%) take children under 18. 15 (65%) are for women only and 0 (0%) for men only; 3 (13%) take healthy volunteers.

Recruiting studies that take each age, of 23
Age	Women	Men
10	1 (4%)	1 (4%)
18	17 (74%)	7 (30%)
30	20 (87%)	7 (30%)
40	22 (96%)	8 (35%)
50	22 (96%)	8 (35%)
65	21 (91%)	8 (35%)
75	19 (83%)	8 (35%)
85	19 (83%)	8 (35%)

Across all 190 studies, recruiting or not: 19% stop at 75 or younger and 8% at 65; 8% take children; 79% are for women only and 0% for men only; 10% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Breast Carcinoma In Situ studies take

Of 21 phase 2 interventional studies under Breast Carcinoma In Situ, half reached primary completion within 37 months of starting, counting those still running.

Start to primary completion	Every sponsor	Industry	Non-industry
Phase 2	37 mo27–75 · 21 studies	—	—
Interventional, no phase	63 mo38–128 · 39 studies	—	63 mo38–128 · 38 studies
Observational	86 mo55–118 · 21 studies	—	—

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 15, 2026.

Results posted3

Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast CancerNov 2, 2026NCT03979508
Improving Patient-Centered Communication in Breast Cancer Through Patient and Provider InterventionsOct 27, 2026NCT04549571
Ruxolitinib for Premalignant Breast DiseaseOct 16, 2026NCT02928978

Studies

Recruiting first, then most recently updated. Showing 50 of 190. Browse all 190 → or search them.